In The News
Carnival wins approval of settlement in P&O ‘cruise from hell’ class action
AAI class action trial delayed as firm waits for $1.7M bank guarantee
Court invalidates Otsuka’s patent for injectable Abilify
S&P fails in bid for all class action expert evidence to be thrown out
Wright Prospecting heirs mull costs order against brother’s litigation funder
AI providers likely shielded from suits by lawyers, experts say
New statutory duty aims to block repeat of Robodebt scandal
MinRes confirms boss will step down over disclosure failures
Former IRExchange execs charged with Corporations Act violations
All judges immune from civil suits for judicial actions, High Court says
Please login to bookmark Close

Generic drug maker Sun Pharma has succeeded in invalidating Otsuka Pharmaceutical’s patent for an injectable, controlled release form of the Japanese drug maker’s top-selling antipsychotic Abilify.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au